NCT00900562 - Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Uterine Cervical CancerEndometrial Cancer

Interventions

DRUG

Zalypsis ( PM00104)

Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion

Trial Locations (4)

OU Cancer Institute, Oklahoma City

UNM (University of New Mexico) Cancer Center, Albuquerque

Massachusetts General Hospital Cancer Center, Boston

Fox Chase Cancer Center, Philadelphia